FDA Approves Drug for Autoimmune Neuropathies

September 13, 2025 በAI የተዘገበ

The FDA approved a new drug for treating autoimmune neuropathies on September 9, 2025, accompanied by discoveries of new autoantibodies and effective complement inhibitors. This development ends 30 years of limited treatment progress in the field.

Japanese researchers identify biological cause of long COVID brain fog

Scientists in Japan have discovered a key molecular change behind the brain fog experienced by many long COVID patients. Using advanced brain imaging, they found increased density of AMPA receptors linked to cognitive impairment. The findings, published on October 1, 2025, could lead to new diagnostics and treatments.

Spotlight on tardive dyskinesia and its management

Tardive dyskinesia remains a significant side effect for patients on long-term antipsychotic medications. Recent medical discussions highlight its symptoms, causes, and emerging treatments. Awareness efforts aim to improve early detection and intervention.

Alzheimer's Biomarker Tests Development

September 11, 2025 በAI የተዘገበ

Regulatory developments were noted for blood-based biomarker tests to detect Alzheimer's disease. These tests represent an emerging tool for early diagnosis. The update was part of a health innovation brief.